CTOs on the Move

Doctor's Best

www.drbvitamins.com

 
We firmly believe in the integration of science research and traditional wisdom as the way that nutritional and herbal supplements will reach their exciting potential.   Founded in 1990 by a pioneering physician committed to science-based alternative health care, Doctor’s Best offers only the most important nutritional supplements. Careful research and precise formula development keeps us at the leading edge of quality, effectiveness, and innovation.   Containing the finest quality raw materials from around the world, Doctor’s Best supplements embody the best that traditional knowledge and current scientific research have to offer in the field of therapeutic nutrition. Countless hours have been spent analyzing ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.drbvitamins.com
  • 197 Avenida La Pata Suite A
    San Clemente, CA USA 92673
  • Phone: 949.498.3628

Executives

Name Title Contact Details

Similar Companies

BioAssay Works

BioAssay Works is a Ijamsville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RDMD

RDMD`s mission is to empower patients and communities to accelerate the development of treatments for rare diseases of all kinds.

Green Point Research

Working to cultivate a better tomorrow by bringing together human, natural & financial resources to grow our businesses and communities.

Pharma-Bio Serv

Pharma-Bio Serv is a Plymouth Meeting, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vascular Biogenics Limited Therapeutics

VBL Therapeutics (NASDAQ: VBLT) is Phase 3 clinical biotechnology company using the machinery of the body to precisely address disease progression. The company has utilized its proprietary gene targeting and antibody platforms to create a pipeline of exquisite solutions for people with difficult to treat cancers and chronic inflammatory diseases. Our lead oncology candidate is Ofravec (VB-111), a first-in-class, targeted anti-cancer gene-therapy agent with a dual mechanism in development to target solid tumors. Ofravec is currently being studied in the OVAL international Phase 3 registration-enabling clinical trial to treat people with platinum-resistant ovarian cancer. Founded in 2000, VBL is based in Modiin, Israel and has recently opened operations in New York.